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Abstract: DFT calculations were employed to explore the
mechanism-based inactivation (MBI) of P450 with the paroxetine. The
drug-enzyme interactions were figured out through studying energy
profiles of three competitive mechanisms. Our DFT analysis revealed 
that, paroxetine is a potent P450’s inhibitor because of the availability
of two active sites for the MBI. The inactivation of P450 at secondary 
amine active site of paroxetine was found to be mainly via hydrogen 
atom transfer (HAT) pathway because of the lower energy demand of
its rate determining step. Our comparative investigation showed that,
LS state is the predominant route in the MBI of P450 by paroxetine at
the methylene dioxo active site as a result of being rebound barrier-
free mechanism. The results of docking analysis are coincided with
the outputs of DFT calculations since the docking pose with the lowest
binding affinity is that for conformation with polar interaction between 
amino group of paroxetine and the oxo moiety of P450’s active site.
Also, the binding between paroxetine and the enzyme was shown to
be likely to occur by the formation of polar bonds, hydrophobic
interactions and π-π interactions. Assessment of the molecular
dynamics (MD) simulations trajectories revealed the favorable 
interaction of paroxetine with P450.
Introduction
Cytochrome P450 (P450) heme-thiolate enzymes are 
predominantly liver-localized enzymes that are responsible for the
catalyzed biotransformation of drugs and xenobiotics [1]. The
biological functions of P450s, such as detoxification and reactive 
metabolites formation, are mainly due to their ability to catalyze
and insert oxygen into large number of substrates [2]. 
Consequently, studying such catalyzed biotransformation might
attract technological applications in many aspects as chemical
and pharmaceutical industries [3].
P450 enzymes are known for their oxidative influence on aryl,
amino and alkyl methylenedioxo compounds [4]. The catalytic
cycle of P450 is usually initiated by the displacement of the distal 
water ligand followed by the binding of the substrate [5]. In this
catalytic cycle, three steps are more prone to inhibition namely: (i)
substrate binding, (ii) molecular oxygen binding after the first
electron transfer and (iii) the actual catalytic oxidation of substrate 
[6]. According to mechanism of inhibition, P450 inhibitors can be
subdivided into three different categories: (1) Reversible binding
inhibitors, which interfere in the catalytic cycle before the
substrate is actually oxidized, these inhibitors are broadly 
reversible competitive or noncompetitive [7], (2) Quasi-irreversible
complexes forming inhibitors, those that function during or after
the oxygen transfer step, and form complexes with the heme iron
atom so they are counted in the class of mechanism-based 
inactivators [7], and (3) Irreversible binding inhibitors, that bind to 
the protein or heme moiety, so they speed up the oxidative
degradation of the prosthetic heme [7]. 
Inhibition of P450 via mechanism-based inactivation (MBI) is
basically not a favorable process, since it has an adverse 
influence on the catalyzed biotransformation processes. However, 
MBI of P450 is beneficial in increasing the probability of attaining
higher degree of selectivity when a specific P450 is targeted [6a, 7c, 
8]. The formation of covalent adduct after the catalyzed
biotransformation of inhibitors into reactive metabolites is the 
main cause for this high selectivity [9]. 
Paroxetine, commonly known as Paxil and Seroxat among others,
is a very potent inhibitor of P450 [11]. Paroxetine is an
antidepressant of selective serotonin reuptake inhibitors (SSRIs)
family [12]. Paroxetine is eliminated by extensive hepatic catalyzed
biotransformation, involving P450’s enzymatic system, and it is
usually oxidized to inactive metabolites [13]. Effectively and
efficiently, paroxetine is used as a pretreatment to inhibit the 
metabolism of tramadol to its active metabolite via inactivating
P450. However, it doesn’t set aside the hypoalgesic effect of
tramadol in human experimental pain models [12].
A precise understanding of P450-drug interaction by in silico 
analysis would afford more reliable predictions for the MBI of
P450 than those already figured out [10]. Docking and Molecular
dynamics (MD) are in-silico techniques that model particles
interactions in a system with initially specified parameters. MD
techniques have been employed by many investigators to find out 
information about the drug-enzyme interactions and reactivities
[14]. Even though large number of studies reported the MD
simulations of P450s, the mechanisms-based drug entry and 
binding into the active site of P450 is still a matter of debate. X-
ray analysis and MD simulations have provided worthy
information about the structural characteristics and variations in
these interactions [15]. In P450 enzymes, the active site is deeply
submerged into the protein and separated from the bulk solvent.
Thus, MD simulations is crucial to identify entry and binding sites
of the drug into the active site cavity [16]. Also, exploring the
structural nature and mechanism of action of P450 by MD
simulations would provide valuable information for designing new
optimal drugs to act as potent P450’s inhibitors and activators.
In this work, a quantum chemical study was reported to explore
the mechanism-based inactivation of P450 by paroxetine. Two 
conceivable active sites on paroxetine for the paroxetine-P450’s
interaction, namely; methylenedioxo and the secondary amine 
group. Consequently, two suggested pathways for the inactivation 
of P450 by paroxetine; the C-H hydroxylation at the
methylenedioxo site and N-H hydroxylation, the latter may
proceed via OAR or HAT. These mechanisms were subjected to 
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extensive DFT studies to understand the mechanistic details
associated with the inactivation of P450 by paroxetine and to 
determine the thermodynamically favorable reaction route. Also,
docking and MD simulations techniques were utilized to perceive 
the structural basis of paroxetine-P450 interactions and the
influence of paroxetine on the conformation of the enzyme.
Results and Discussion
Active site for Paroxetine
From the chemical point of view the chemical reactive sites of
paroxetine can easily deduced from the difference of polarity of its
atoms. However, in order to get a realistic approach to the
biological environment that might be involved in their interaction
we choose docking paroxetine onto the binding site of the P450.
After many intents the best docking pose for the ligand was
selected according to its conformation and docking energy. The
low binding affinity (-8.7 kcal/mol) suggests the formation of a
stable paroxetine-P450 complex. The applied docking grid box
was set at 30 x 30 x 30 (x,y,z) and the binding site residues were
Arg108, Ser209, Phe100, Phe114, Phe476, Leu361, Leu362,
Leu366, Val292, Thr301, Thr304, Ile205, Glu300 and Val479.
There were three hydrogen bonding interactions between 
paroxetine and the enzyme (Figure 4) because of the availability
of polar hydrogens in the inhibitor structure. The availability of π-
π interactions between aromatic species is a leading factor in
molecular recognition and plays a crucial role in adapting the
conformation of paroxetine in the binding pocket of the enzyme.
The results of docking analysis of paroxetine-P450 complex
showed three phenylalanine residues at the binding site; Phe100,
Phe114 and Phe476. These residues have the ability to create 
electrostatically favorable π-π interactions that could possibly
interact with the aromatic rings of the inhibitor. This is confirmed
by the fact that paroxetine interacts with phenylalanine residues
by the electrostatically attractive interaction edge-to-face and
offset stacked orientation types rather than the unfavorable face-
to-face and edge-to-edge orientations [32]. It is interesting to note
that the best docking pose is that conformation with the polar bond
between the secondary amine and the oxo moiety of P450’s
active site which might direct our DFT calculations. The results of
molecular docking analysis bring to light the fact that interaction
between paroxetine and the enzyme is predominant by the 
formation of polar bonds and π-π interactions. Also, these outputs
shed the light on the contribution of not only active sites 
(methylenedioxo and amino) but also aromatic rings in paroxetine 
structure in the MBI of P450 by the electrostatically favored π-π 
interactions. The surface representation of free P450 and
paroxetine bound to the internal cavity of P450 is shown in Figure 
5. Generally, molecular docking analysis confirms the potency of
paroxetine as P450 inhibitor.
Hydroxylation of P450.
Localized the site of action of paroxetine the inhibition of the
enzyme might occur in different ways. Let’s first recover the state
of works done computationally on the P450’s reaction mechanism.
Previously reported theoretical studies on P450’s active site
concerned mainly C-H hydroxylation [17], C=C epoxidation [18] and 
heteroatoms oxidation [19]. C-H bond hydroxylation, catalyzed by
P450, is revealed as an important metabolic process in
detoxifying toxic and endogenous materials [6a]. These
mechanisms were subjected to intensive investigations,
nevertheless, its characteristics are still a matter of debate.
Generally, this mechanism was agreed to proceed via an initial
hydrogen abstraction from the C-H bond by means of compound
I (Cpd I), that was modeled by ferryl-oxene (Por+•FeO) species
with HS‾ as a proximal ligand and stands for P450’s active site [17b, 
20]. Subsequently, the alkyl radical rebound to the oxygen of the
hydroxy ferryl species generating ferryl-hydroxylated C-H 
complex, then the alcohol is released and the P450’s resting state
is retrieved by coordinating to the water ligand [17b, 20]. In human, 
secondary amine xenobiotics is catalytically metabolized by 
P450s leading to the formation of hydroxylamines [21]. So far, four
mechanisms are conceivable for the N-hydroxylation of
secondary alkylamines; hydrogen atom transfer (HAT), oxygen 
addition rearrangement (OAR), single-electron transfer (SET) and 
proton transfer (PT) [22]. In HAT mechanism, H-atom is abstracted 
from the nitrogen of the amine to the oxygen of the ferryl oxo
center and subsequently, a rebound of the alkyl radical to the
oxygen of the iron-hydroxyl species yielding hydroxylamine 
ArNHOH [23]. While in OAR mechanism, the N-oxide obtained 
from the addition of FeO oxygen to N of the amine rearranges to
N-hydroxylamine [23]. A single electron is transferred in the SET
mechanism from the amine to the FeO followed by proton transfer
and finally the amine radical rebound to the ferric hydroxy species
[24]. This intermediate amine radical could undergo a two-electron 
transfer (TET) process to afford an aminyl cation [23]. In the proton
transfer mechanism (PT), a proton is transferred from the amine
to FeOO2- to form the ferric hydroperoxide anion FeOOH- [24].
Scheme 1. Model for our DFT calculations for the conceivable pathways for
paroxetine-P450 interactions.
Generally, P450 mechanisms involve two-state reactivity (TSR)
nascent from the two degenerate ground states of Cpd I that was
modeled by ferryl-oxene (Por+•FeO) species with HS‾ as a 
proximal ligand, the TSR are low-spin (LS, doublet) and high-spin
(HS, quartet) [17b, 25]. The TSR hypothesis assumes a competition
between two comparable reaction routes, and the prevailing 
pathway is substrate and environmental dependent [26]. A perfect 
C-H hydroxylation mechanism exposes a doubled reaction route 
because of the HS and LS states, these two paths remain 
energetically adjacent in the H-abstraction stage then bifurcate 
during the rebound step [6a]. In this mechanism, the quartet state
route shows a significant rebound transition state energy barrier 
while the LS state pathway is concerted with insignificant radical
intermediate lifetime [19c, 27]. The situation in case of hydroxylation
of alkylamines is a bit more complicated because of the presence
of two competitive reaction routes; HAT and OAR. Where a slight
energetic preference for the HAT was detected, and the highest
transition state energy barrier was observed for both LS and HS
states [19b]. Nevertheless, in another study the two paths were
most likely to occur. On the contrary to the previously reported,
the rearrangement step in the OAR mechanism was shown to
pass through a higher energy barrier, and that for the HAT 
mechanism the rebound step process via barrier-free mode in the
LS state [23]. 
In the present study the choice of paroxetine tries to recover the
different possibilities discussed above and so the three mentioned 
mechanisms: The C-H hydroxylation where MBI mechanism is
involved and N-H hydroxylation where both HAT and OAR
pathways are expected. The probability of both processes to take 
place is similar since the binding energy of paroxetine with Cpd I
through C-H bond is slightly inferior than the interaction with its N-
H group. In fact, the energy involved in the former is about -1.5 
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whereas in the later is about -2.05 kcal/mol at the higher level of
theory. The mechanisms of P450 are susceptible to follow
different routes to throw off water molecule. Our computational
efforts were carried out to recover all these possibilities. Different
pathways for the MBI of P450 by paroxetine were assessed by
setting up a model for the possible active sites of the P450-
paroxetine interaction (Scheme 1). Two possible pathways, Paths
A and B, for the MBI of P450 by paroxetine were examined, which 
were discriminated by the paroxetine’s active site attacked by the
oxo ferryl moiety of P450 (scheme 2). In path A, the catalyzed 
biotransformation process is mainly proceeding via C-H 
hydroxylation of the methylene dioxo moiety of paroxetine 
(scheme 3), while in path B the N-hydroxylation of the secondary
amine is the main route responsible for the MBI of P450.
Consequently, the four mechanisms underlying the N-
hydroxylation by P450 have been discussed (scheme 4) [23-24]. 
Figures 1 and 2 show the obtained energy profiles (in kcal/mol)
and key geometric features at the UB3LYP/B2//B1+ZPE(B1) and
UB3LYP (SCRF)/B2//B1+ZPE(B1) levels for both the doublet and
quartet states of The MBI of P450 by paroxetine at methylene 
dioxo and secondary amine active sites of paroxetine,
respectively.
Methylen Hydroxylation (path A): Initially, the energy of the
reactant complex (2,4RCm) in both doublet and quartet states is
stabilized by a weak hydrogen bonding interaction between a
hydrogen atom at the methylene dioxo active site of paroxetine 
and the oxo moiety of the ferryl oxo species. In this stage the LS
and HS states are degenerated with a negligible energy difference,
about 0.08 kcal/mol. The process begins by the rate determining 
step for both LS and HS pathways in which the hydrogen atom is 
transferred form methylene dioxo of paroxetine to the FeIV=O of
Cpd I (2,4TS-Hm). The energy barrier of the quartet H-abstraction 
transition state (4TS-Hm) is higher than its doublet parallel (2TS-
Hm) by ≈ 1.7 kcal mol-1, this discrimination could be noticed from
the variation of the arrangement O•••H•••C bond distances in both
LS and HS states. Moreover, the two transition states, 2,4TS-Hm,
possess the geometrical features of H-abstraction transition 
states with a nearly collinear arrangement of the O•••H•••C moiety 
(O•••H•••C bond angles of 170.5-175o) [17b, 28]. It should be
mentioned that, most of the structural characteristics of H-
abstraction transitions states are included, including shortening of
the Fe-S bond length, lengthening of the Fe-O bond length, light 
breathing of the porphyrin, a semi resting of iron into the porphyrin 
plane and the corresponding imaginary frequency [17b, 24]. As
previously reported, the LS and HS H-abstraction energy barriers
of paroxetine-P450 interaction are not discriminated because this
reaction is governed by TSR principle [6a, 17b]. Subsequently, a
radical intermediate (2,4INTm) is formed after the H-abstraction 
from paroxetine to the ferryl oxo species, this intermediate is a
complex of the paroxetine methylene dioxo radical with
FeOH(PorSH). In this complex, the CH• of paroxetine is still
connected to the OH group of the ferryl hydroxy porphyrin [28a]. As
expected, the LS state (2INTm) is slightly lower than its HS
counterpart (4INTm) by energy difference less than 0.5 kcal mol-1 
which confirm the proceeding of this reaction via TSR as
previously mentioned.
Scheme 2. The general mechanisms for the quasi-irreversible inactivation of P450 enzymes by paroxetine at the two conceivable active sites; Path A: methylene
dioxo hydroxylation; Path B: N-hydroxylation of the secondary amine.
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After radical intermediate complexes formation (2,4INTm), a
rebound reaction occurs for these intermediates to complete its
catalytic transformation. This reaction involves the rebound of 
these intermediates to OH of ferryl hydroxy species to form
hydroxylated paroxetine within methylene dioxo active site (2,4P-
OHm) and Fe(PorSH). It is apparent that, the LS rebound process
proceeds via energy barrier-free mode (concerted mechanism), 
while the HS pathway involves a two-step process with
considerable rebound energy barrier as previously reported for C-
H hydroxylation [17b, 29]. These variations in kinetics between HS
and LS reaction pathways assume that C-H hydroxylation of
paroxetine at the methylene dioxo active site is superior for the 
LS route over its HS counterpart.
Amine hydroxylation (path B): the reaction energy profile for
HAT and OAR routes for the MBI of paroxetine-p450’s interaction 
along with the geometrical features are represented in figure 2.
The HAT and OAR mechanisms are directed to right and left,
respectively. Analogue to the methylene dioxo pathway, the 
reactant complexes in LS and HS states (2,4RC) are also stabilized
by hydrogen bonding interaction between the hydrogen of the 
secondary amine site and the oxo center of Cpd I. In the 2,4RC,
the formed hydrogen bond is stronger than that in case of 2,4RCm
(O•••H distance for 2,4RC ∼ 2.08 Å versus ∼ 2.2 Å for 2,4RCm), this
is mainly due to the electronegativity differences between the
atoms involved (nitrogen and carbon). Obviously, a quite meager
H-abstraction energy barrier (2,4TSH) in the PCM-protein imitated 
model for both LS and HS state of the HAT route (2.9 and 2.6 kcal
mol-1 for LS and HS, respectively) afforded radical cluster
intermediate (2,4INTH) as iron-hydroxy porphyrin species
(PorFeIVOH). Oppositely, the initial oxygen addition to the
nitrogen lone pair energy barriers (2,4TSO) calculated for the OAR
pathway are generally higher than those obtained for the HAT H-
abstraction transition state pathway (7 and 5.7 kcal mol-1 for LS
and HS, respectively) (see figure 2). It should be noted that, the
energy barriers of the first transition states for both methylene 
dioxo (2,4TS-Hm; 7.1 and 5.4 kcal mol-1 for HS and LS, 
respectively) and OAR (2,4TSO; 7 and 5.7 kcal mol-1 for LS and HS, 
respectively) pathways are nearly equal. This observation is of
particular interest since it shed the light on suggesting the same 
probability for initiating both mechanisms. In OAR mechanism,
the formed N-oxide as an intermediate complex through O
addition to N lone pair (2,4INTO) will be mainly in the doublet state
(13.8 and 15.2 kcal mol-1 for both HS and LS, respectively) as
commonly known for nitrogen oxidation [19b].
Subsequent to the secondary amino radical intermediate
formation in HAT mechanism, the ferryl hydroxy moiety rebound
to the amino radical to afford the hydroxylation product (2,4POH).
Contrary to the previously reported in the literature [23], the
hydroxylation product (POH) in both LS and HS states is formed
via significant rebound barriers with LS and HS states being
degenerated. Also, the energies of rebound barriers in LS and HS
states (2,4TS-rebH) are higher than their analogues of H-
abstraction transition states (2,4TSH) in contrast to what is depicted
for the C-H hydroxylation mechanisms, where the energies of the
rebound barriers were permanently lower than H-abstraction 
barriers [30].
Scheme 3. Methylene dioxo hydroxylation of paroxetine by P450
Scheme 4. Alternative mechanisms for the N-hydroxylation of paroxetine by 
P450, HAT: H atom transfer; OAR: oxygen addition rearrangement; SET: single-
electron transfer; TET: two-electron transfer; PT: proton transfer.
The hydroxylation product (2,4POH) form the OAR route is obtained
from the N-oxide intermediate (2,4INTO) via H atom transfer from
N to O. As expected, the energies of the rebound barriers in this
mechanism is larger than those of the O addition step (2,4TS-rebo; 
~25 and 14 kcal mol-1 for HS and LS, respectively). Accordingly, 
this H atom transfer step would express the overall rate
determining step in the OAR pathway. It has been always
depicted a relatively larger OAR rebound energy barriers for LS
and HS states [31]. In contrast, our findings showed a smaller
rebound barrier for the LS state (~14 kcal mol-1) than those
previously reported for the N-hydroxylation [23, 31] suggesting an
increased probability for OAR mechanism to take part in the
catalyzed biotransformation of paroxetine. However, the OAR
mechanism is still thermodynamically less favorable pathway for
the N-hydroxylation mechanism of paroxetine as a result of the 
higher energy demand of its rate determining step than that of
HAT route.
Overall, our findings for the N-hydroxylation of paroxetine 
assumed that, the OAR pathway cannot contend against the HAT 
pathway because of the higher energy requirements of the rate 
determining step of the former. Also, the proceeding of the OAR
pathway via LS state with a rebound barrier lower than expected 
(~14 kcal mol-1) would suggest a better probability for the OAR
route to share in the MBI of P450 by paroxetine than those
previously reported for OAR pathway.
What is next after hydroxylation of paroxetine? As it is
represented in scheme 2 in both scenarios, path A and path B,
the final step is the lost of water molecule and the interaction of
paroxetine with heme. To overcome the mechanistic of these 
processes, figure 3 reports the calculated energy profile (in
kcal/mol) and key geometric features at the same level of theory 
for hydroxy paroxetine complex at the methylene dioxo and amino 
active sites. The obtained profile for dehydration of hydroxylated 
paroxetine complex in both mechanisms revealed the tendency of
paroxetine to coordinate tightly to the heme iron atom. This
mechanism is partially responsible for the inhibition of P450. The
transition states for the hydrogen transfer from paroxetine to the
added hydroxyl (2.4TS-Dm for methylenedioxo mechanism and
2.4TS-DN for secondary amine pathway) suggest the elimination of 
water form hydroxylated paroxetine complex to afford the
paroxetine-heme coordinated complex (2.4P-Cm and 2.4P-CN for
methylenedioxo and secondary amine deactivations,
respectively). The change in bond distances between C-O and N-
O along these pathways in both mechanisms behold a
significance probability for the dehydration steps to occur. The
considerable energies of transition states in both mechanisms 
and the close energies of reactants and products in
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methylenedioxo route leads to the conclusion that the inactivation
of P450 by paroxetine is a quasi-irreversible process under
unique experimental conditions [4].
Our comparative study revealed the proceeding of the MBI of
P450 by paroxetine at the methylene dioxo reactive site by a LS 
state mechanism with rebound barrier-free mode. As well, the
inactivation of P450 at the amino group of paroxetine is obviously
proceed through HAT pathway because of the lower energy
requirements of its rate determining step. Interestingly, the nearly
equal total energy demand for the inactivation of P450 by
paroxetine at the methylene dioxo active (LS state, 2TS-Hm ~ 5.4
kcal mol-1 , free rebound barrier) and at the secondary amine
active site by HAT mechanism (LS or HS state, 2,4TSH ~ 2.9 and 
2.6 kcal mol-1 for LS and HS, respectively; 2,4TS-rebH ~ 7 and 6.7 
kcal mol-1 for LS and HS, respectively) would suggest an equal 
probability for both reaction to occur. This fact leads to the 
conclusion that paroxetine is a potent P450’s inhibitor because of
the presence of two reactive sites available for P450 interaction.
In addition to, the increased share of OAR pathway besides HAT
pathway in N-hydroxylation of paroxetine due to 
thermodynamically possible LS state rebound than those
commonly known for OAR mechanism.
Figure 1. Energy profiles (in kcal mol-1) for inactivation of P450 at the methylene dioxo active site of paroxetine calculated at the B3LYP/B2//B1+ZPE(B1) (in




                   






                     





Figure 2. Energy profiles (in kcal mol-1) for inactivation of P450 at the secondary amine active site of paroxetine obtained at the B3LYP/B2//B1+ZPE(B1) (in
parentheses) and the B3LYP (SCRF)/B2//B1+ZPE(B1) levels, along with geometrical features for the reaction species in both LS and HS (in parentheses) states.
Figure 3. Energy profiles (in kcal mol-1) for the coordination of the dehydrated hydroxy paroxetine complex to the iron atom of the heme at the methylene dioxo (A)
and amino (B) active sites obtained at the B3LYP/B2//B1+ZPE(B1) (in parentheses) and the B3LYP (SCRF)/B2//B1+ZPE(B1) levels, along with geometrical features





    
         
    
     
        
       
  
      
    
      
        
      
    
  
 
        
    
           
     
      
      
    
      
    
          
         
 
          
          
       
         
        
        
       
     
  
        
      
           
         
       
         
     
     
          




          
 
Molecular Dynamics Simulations
To show up the stability of paroxetine in an enzyme environment,
its interaction with P450 was screened by performing MD
simulations for P450 and P450-paroxetine complex with intensive 
analysis of the MD trajectories including root mean square 
deviations (RMSD), hydrogen bonding profile, root mean square
fluctuation (RMSF), radius of gyration (Rg) and solvent accessible
surface area (SAS).
The paroxetine interactions with the active site amino acid
residues of P450 were examined during the 10 ns MD simulation 
through investigating the hydrogen bonding profile of protein– 
ligand interactions as shown in Figure 6. The hydrogen bonding
profile of paroxetine-P450 complex revealed three hydrogen
bonds formation behavior with two amino acids residues and the 
heme residue in the P450 active pocket, two H-bond is stable and 
the third is weaker throughout the 10 ns MD simulations.
The stability and integrity of the system (enzyme, water, ions, etc.)
during the entire 10 ns MD simulations were studied by analyzing 
the RMSDs in water environment of the backbone atoms of P450
as a function of time for the protein and paroxetine-P450 complex,
as shown in Figure 7. Analysis of this plot indicated that P450 and
paroxetine-P450 complex attained equilibrium and oscillated
around the average value after about 3 ns and remains stable to 
the end of simulation. Consequently, this RMSD protein backbone
pattern reflects stability and equilibrium during the course of
simulation time (between 3 and 10 ns). Reduced values of RMSD
of paroxetine-P450 complex infers that the binding of paroxetine
to P450 lowers the protein movement degrees of freedom.
Besides, the radius of gyration (Rg) values of free P450 and
paroxetine-P450 complex was calculated as a function of time, as
represented in Figure 8. The Rg values outline the protein's 
compactness with protein folding and unfolding along the 10 ns of
MD simulations through thermodynamic basis. Initially, the Rg
value was 2.28 nm then its value was stabilized at approximately
3000 ps, indicating that equilibrium was achieved after this time, 
as represented in Figure 8. The compactness of P450 structure
during the simulation was estimated from the decreasing in the 
radius of gyration for backbone atoms. Moreover, Figure 8 implies
that Rg assessment of P450 is not altered by the complexation 
with paroxetine. This indicates that the environment of P450 is not
changed during the interaction with paroxetine. In addition, the
total solvent accessible surface area (SAS) was evaluated for
P450 in its native form and liganded form during 10 ns MD
simulations as seen in Figure 9. Interestingly, the divergence
profile of SAS in free P450 and P450-drug complex is similar to 
the change in Rg values, this resemblance asserts the precision
of the results of the MD simulations.





     
 
          
   
          
       
         
     
          
        
        
    
         
     
      
 
 




      
  
 
       
       
 
 
Figure 5. Surface representation of the native P450 (A) and paroxetine bound P450 (B) structures.
An elaborate assessment of the RMSF behavior of native P450
and P450 bound complex was carried out and the analyzed 
results represent the fluctuations of amino acids in free and
catalyzed sites (Figure 10). This plot was recorded as against
residue number based on 10 ns trajectory. The obtained RMSF
profile manifests fluctuations at the catalytic site of P450 in the 
range of 0.05 to 0.47 nm. As shown in Figure 10, no significant 
fluctuations were disclosed at paroxetine binding site in the
paroxetine-P450 complex compared to the free P450 protein.
Thus, the obtained data is clearly lead to the conclusion that
residues at the internal cavity displayed low fluctuations for the
drug, and paroxetine binding cavity architecture is nearly stick
around its rigidity disposal during the 10 ns MD simulations.
during 10 ns MD simulation.
Figure 6. Total hydrogen bond intensity after 10 ns MD simulations for the 
Paroxetine-P450 complex.
Figure 8. Radius of gyration (Rg) of the backbone of P450 and Paroxetine-
P450 complex during 10 ns MD simulation.




      




     
       
 
     
       
       
     
     
    
       
      
   
      
        
      
       
      
    
    
       
      
       
    
     




          
    
    
   
       
   
        
        
          
     
    
       
   
        
      
       
      
        
        
       
    
 
  
       
        
         
  
          
          
       
      
      
             
     
       
        
        
           
    
   
  
 
   
      
      
       
         
      
       
        
        
       
  
     
     
        
      
         
      
            
        
    
     
        
        
   
  
 
Figure 9. Total solvent accessible surface (SAS) of P450 and Paroxetine-
P450 complex during 10 ns MD simulation.
Figure 10. Root mean square fluctuation (RMSF) values of P450 and 
Paroxetine-P450 complex during 10 ns MD simulation.
Conclusion
In conclusion, we have performed intensive computational 
analysis to figure out how paroxetine act as potent P450 inhibitor
in its MBI. Our calculations provide several new insights. The
possible mechanisms for the MBI of P450 by paroxetine involve 
C-H hydroxylation and N-hydroxylation at two different active sites
on paroxetine structure. Both mechanisms are likely to occur
indicating the potency of paroxetine as P450 inhibitor. Docking
and MD simulations were carried out to inspect structural features
and binding mechanisms. Docking analysis revealed the activity
of paroxetine against P450 by the formation of polar bonds and 
π-π interactions with phenylalanine residues. One polar bond was
detected against the oxo moiety of the heme. This information is
of particular interest since its good agreement with our DFT study.
The result of docking was utilized for MD simulations which 
uncover valuable information to detect the effect of paroxetine 
binding on P450’s conformational variation and the stability of
paroxetine-P450 complex in aqueous medium. MD simulations
studies revealed the stabilization of protein and protein-drug 
complexes at around 3000 ps. Also, the similarity of free P450 
and the complex’s atomic fluctuations scheme suggests the 
rigidity of the paroxetine-binding site nature during the 10 ns MD
simulations. Rg values reflect the stability of the complex and that
the conformation has not altered relative to P450’s conformation.
Experimental Section
DFT studies
DFT calculations in this work were performed by using Gaussian
09 [33] package for the mechanisms represented in scheme 2. The 
active site of P450 (Cpd I) was modeled as oxo-ferryl porphyrin 
[25, 28b, 34] Fe4+O2-species (C20N4H12)-(SH)-. Full geometry
optimizations for all species in doublet and quartet states were 
employed using the unrestricted B3LYP [35] functional in
combination with the double-ζ LANL2DZ basis set for iron and 6-
31G* basis set for the other atoms, denoted BS1. Frequency
calculations were also performed at the same level to depict the
stationary points, obtain zero-point energy (ZPE), to calculate free 
energy, to evaluate the imaginary frequency for the transition 
states and to assure that ground states having no imaginary 
frequency. Thereafter, single-point energy calculations were 
carried out with the LANL2DZ (F) (Fe)/6-311+G** (H,C,N,O,S)
basis set (denoted BS2) in gas phase (ɛ=1) and in chlorobenzene
solvent (ɛ =5.7) to mimic the bulk polarity influence of the protein 
environment [29, 36], for the solvation effect, the self-consistent
reaction field (SCRF) method was employed using the polarizable
continuum model (PCM) solvation method [37]. In addition to, IRC
calculations were also performed for several transition states to
depict their pathways [38].
Molecular Docking
Molecular docking investigation was performed by using
Autodock Tools (ADT) v1.5.6 and AutoDock Vina software [39]. 
Results were analyzed and visualized by using PyMOL v2.3.2.
The crystallized three-dimensional structure of cytochrome P450 
(PDB ID: 3NV5, 2.4 A° resolution) was obtained from Protein Data
Bank (PDB). Missing residues in the crystal structure of 3NV5
were added using MODELLER 9.22 [40] by the guidance of the 
3NV6 (PDB ID) crystal structure. The Gaussian 09 package [33] 
optimized structure of the paroxetine at the B3LYP level [35b-d] with
the 6-311G (d, p) basis set [41] was used as initial structures for
docking and MD simulations. Paroxetine was docked at various
sites in the access channel of P450. Macromolecules were
visualized and separated from ligand, solvent and unneeded
residues by using UCSF Chimera [42]. Isolated protein receptor
was prepared for docking by optimization by means of ADT, this
optimization includes addition of polar hydrogens and setting the 
grid box according to the best configuration of the active site 
amino acid residues [43]. 
Molecular dynamics simulations
The complex of paroxetine (PDB ID: 3NV5) with the lowest
binding free energy was selected for MD simulation. Water
molecules were stripped out from paroxetine-P450 complex. The
Dundee PRODRG 2.5 server was utilized to build the starting
topology parameters of the paroxetine [44], these parameters were
implanted into the topology parameters of the enzyme. The 10 ns
MD simulations of P450 and paroxetine-P450 complexes were
carried out using GROMACS 2019.4 software packages [45] with
the GROMOS9643a1 force field [46]. The enzyme and drugs-
enzyme complexes were placed in a dodecahedron box with the 
periodic boundary conditions, the box volume was 591.64 nm3 . 
The simple point charge (SPC) water model was employed and 
three chloride counter-ions were added to attain electroneutrality
[47]. The steepest descent energy minimization method was used
for 10 ps to relieve the thermodynamically less favorable
interactions [48]. Thereafter, systems were equilibrated on two
stages at a temperature of 300 K for 100 ps each; NVT and NPT
ensembles [49]. Finally, the 10 ns MD simulation was executed at 
300 K temperature and 1 bar pressure. The long-range
electrostatic terms were contained using the particle mesh Ewald
algorithm [50], and the motion equations were employed by
applying the leap-frog integrator with the time-step of 2 fs.
Trajectories were visualized using VMD [51] and UCSF Chimera 





        
    
 
       
    
 
    
    
 
      
         
   
        
 
  
       
       
     
          
  
        
            
         
 
    
      
 
   
  
    
 
  
     
    






      
         
            
            
   
      
            
        
           
   
    
        
        
         
            
  
     
 
  
     
 
     
 
      
 
          
    
         
 
          
   
     
          
            
   
      
 
    
 
      
 
   
            
               
            
 
                 
             
                
                
              
              
              
        
   
 
       
           
      
    
        
       
 
     
          
 
       
  
    
 
 
   
  
          
 
             
  
   
    
       
        
    
   
             
 
       
     
      
  
    
 
    
           
          
 
      
        
 
Acknowledgements
This work has DGI Projects no. CTQ2015-63997-C2, Authors
also thank the Centro de Computación Científica of the UAM for
the generous support and computing time. 
Keywords Cytochrome P450 • Paroxetine • Catalyzed
biotransformation • Mechanism-based inactivation • Reaction
mechanism
[1] D. W. Nebert and T. P. Dalton, Nature reviews. Cancer 2006, 6, 947.
[2] M. Sono, M. P. Roach, E. D. Coulter and J. H. Dawson, Chemical Reviews
1996, 96, 2841-2888.
[3] a) L. P. Wackett, M. J. Sadowsky, L. M. Newman, H.-G. Hur and S. Li, Nature
1994, 368, 627-629; b) C. Duport, R. Spagnoli, E. Degryse and D. Pompon,
Nature biotechnology 1998, 16, 186-189.
[4] M. A. Correia and P. R. O. de Montellano in Inhibition of cytochrome P450
enzymes, Springer, 2005, pp. 247-322.
[5] S. Nagano, H. Li, H. Shimizu, C. Nishida, H. Ogura, P. R. O. de Montellano
and T. L. Poulos, Journal of Biological Chemistry 2003, 278, 44886-44893.
[6] a) P. R. O. De Montellano, Cytochrome P450: structure, mechanism, and
biochemistry, Springer Science & Business Media, 2005, p; b) A. Rodrigues, D. 
Fernandez, M. Nosarzewski, W. Pierce Jr and R. Prough, Chemical research in
toxicology 1991, 4, 281-289.
[7] a) M. Murray and G. F. Reidy, Pharmacol Rev 1990, 42, 85-101; b) S. Rendic 
and F. J. D. Carlo, Drug metabolism reviews 1997, 29, 413-580; c) U. M. Kent,
M. Jushchhyshyn and P. F. Hollenberg, Current drug metabolism 2001, 2, 215-
243.
[8] P. Chuanprasit, S. H. Goh and H. Hirao, ACS Catalysis 2015, 5, 2952-2960.
[9] H. Hirao, Z. H. Cheong and X. Wang, The Journal of Physical Chemistry B
2012, 116, 7787-7794.
[10] S. Shaik, S. Cohen, Y. Wang, H. Chen, D. Kumar and W. Thiel, Chemical
reviews 2009, 110, 949-1017.
[11] K. Brøsen, L. F. Gram and P. Kragh-Sørensen, Therapeutic drug monitoring 
1991, 13, 177-182.
[12] S. Laugesen, T. P. Enggaard, R. S. Pedersen, S. H. Sindrup and K. Brøsen, 
Clinical Pharmacology & Therapeutics 2005, 77, 312-323.
[13] B. G. Pollock, Am J Psychiatry 1996, 1, 53.
[14] R. R. Naik, N. S. Gandhi, M. Thakur and V. Nanda, Food chemistry 2019, 
125182.
[15] S. Gharaghani, T. Khayamian and F. J. S. C. Keshavarz, 2012, 23, 341-
350.
[16] S. K. Lüdemann, V. Lounnas and R. C. J. J. o. m. b. Wade, 2000, 303, 797-
811.
[17] a) S. Shaik, D. Kumar and S. P. de Visser, Journal of the American 
Chemical Society 2008, 130, 14016-14016; b) F. Ogliaro, N. Harris, S. Cohen,
M. Filatov, S. P. de Visser and S. Shaik, Journal of the American Chemical
Society 2000, 122, 8977-8989; c) C. Li, W. Wu, D. Kumar and S. Shaik, Journal
of the American Chemical Society 2006, 128, 394-395.
[18] a) S. P. de Visser, F. Ogliaro and S. Shaik, Angewandte Chemie 2001, 113, 
2955-2958; b) S. P. de Visser, F. Ogliaro, N. Harris and S. Shaik, Journal of the 
American Chemical Society 2001, 123, 3037-3047; c) D. Kumar, B.
Karamzadeh, G. N. Sastry and S. P. de Visser, Journal of the American 
Chemical Society 2010, 132, 7656-7667.
[19] a) C. Li, L. Zhang, C. Zhang, H. Hirao, W. Wu and S. Shaik, Angewandte
Chemie International Edition 2007, 46, 8168-8170; b) P. Rydberg, U. Ryde and 
L. Olsen, Journal of chemical theory and computation 2008, 4, 1369-1377; c) C.
Li, W. Wu, K. B. Cho and S. Shaik, Chemistry–A European Journal 2009, 15, 
8492-8503; d) S. Shaik, Y. Wang, H. Chen, J. Song and R. Meir, Faraday
Discussions 2010, 145, 49-70.
[20] J. T. Groves and D. V. Adhyam, Journal of the American Chemical Society 
1984, 106, 2177-2181.
[21] F. P. Guengerich, The AAPS journal 2006, 8, E101-E111.
[22] P. Rydberg and L. Olsen, Journal of chemical theory and computation 2011, 
7, 3399-3404.
[23] L. Ji and G. Schüürmann, Angewandte Chemie International Edition 2013, 
52, 744-748.
[24] L. Ji and G. Schüürmann, Chemical research in toxicology 2015, 28, 585-
596.
[25] S. P. de Visser, F. Ogliaro, P. K. Sharma and S. Shaik, Journal of the 
American Chemical Society 2002, 124, 11809-11826.
[26] P. R. O. de Montellano and J. J. De Voss in Substrate oxidation by
cytochrome P450 enzymes, Springer, 2005, pp. 183-245.
[27] Y. Wang, D. Kumar, C. Yang, K. Han and S. Shaik, The Journal of Physical
Chemistry B 2007, 111, 7700-7710.
[28] a) H. Basch, K. Mogi, D. G. Musaev and K. Morokuma, Journal of the 
American Chemical Society 1999, 121, 7249-7256; b) F. Ogliaro, N. Harris, S.
Cohen, M. Filatov, S. P. de Visser and S. Shaik, Journal of the American 
Chemical Society 2000, 122, 8977-8989.
[29] L. Ji and G. Schüürmann, The Journal of Physical Chemistry B 2012, 116, 
903-912.
[30] S. Shaik, D. Kumar, S. P. de Visser, A. Altun and W. Thiel, Chemical
reviews 2005, 105, 2279-2328.
[31] S. T. Seger, P. Rydberg and L. Olsen, Chemical research in toxicology 2015, 
28, 597-603.
[32] C. A. Hunter, J. Singh and J. M. J. J. o. m. b. Thornton, 1991, 218, 837-846.
[33] M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. 
R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G. A. Petersson, H.
Nakatsuji, M. Caricato, X. Li, H. P. Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng,
J. L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. 
Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J. A. Montgomery
Jr., J. E. Peralta, F. Ogliaro, M. J. Bearpark, J. Heyd, E. N. Brothers, K. N. Kudin,
V. N. Staroverov, R. Kobayashi, J. Normand, K. Raghavachari, A. P. Rendell, J.
C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, N. Rega, N. J. Millam, M. Klene,
J. E. Knox, J. B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E.
Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, R.
L. Martin, K. Morokuma, V. G. Zakrzewski, G. A. Voth, P. Salvador, J. J.
Dannenberg, S. Dapprich, A. D. Daniels, Ö. Farkas, J. B. Foresman, J. V. Ortiz,
J. Cioslowski and D. J. Fox, Wallingford, CT 2009.
[34] C. Li, W. Wu, K. B. Cho and S. Shaik, Chemistry-A European Journal 2009, 
15, 8492-8503.
[35] a) A. D. Becke, The Journal of chemical physics 1992, 96, 2155-2160; b)
A. D. Becke, The Journal of Chemical Physics 1993, 98, 5648-5652; c) A. D.
Becke, Physical review A 1988, 38, 3098; d) C. Lee, W. Yang and R. G. Parr, 
Physical review B 1988, 37, 785.
[36] a) B. Honig and A. Nicholls, Science 1995, 268, 1144-1149; b) C. N. Schutz 
and A. Warshel, Proteins: Structure, Function, and Bioinformatics 2001, 44, 
400-417.
[37] a) S. Miertuš, E. Scrocco and J. Tomasi, Chemical Physics 1981, 55, 117-
129; b) J. Tomasi, B. Mennucci and R. Cammi, Chemical reviews 2005, 105, 
2999-3094.
[38] K. Fukui in The path of chemical reactions—the IRC approach, World
Scientific, 1997, pp. 471-476.
[39] O. Trott and A. J. Olson, Journal of computational chemistry 2010, 31, 455-
461.
[40] A. Šali and T. L. J. J. o. m. b. Blundell, 1993, 234, 779-815.
[41] W. J. Hehre, L. Radom, P. v. R. Schleyer and J. A. Pople, Ab initio molecular
orbital theory, Wiley New York et al., 1986, p.
[42] E. F. Pettersen, T. D. Goddard, C. C. Huang, G. S. Couch, D. M. Greenblatt, 
E. C. Meng and T. E. Ferrin, Journal of computational chemistry 2004, 25, 1605-
1612.
[43] R. T. Nolte, G. B. Wisely, S. Westin, J. E. Cobb, M. H. Lambert, R. 
Kurokawa, M. G. Rosenfeld, T. M. Willson, C. K. Glass and M. V. Milburn,
Nature 1998, 395, 137.
[44] A. W. Schüttelkopf and D. M. Van Aalten, Acta Crystallographica Section 
D: Biological Crystallography 2004, 60, 1355-1363.
[45] a) H. J. Berendsen, D. van der Spoel and R. van Drunen, Computer physics
communications 1995, 91, 43-56; b) E. Lindahl, B. Hess and D. Van Der Spoel,
Molecular modeling annual 2001, 7, 306-317.
[46] W. F. van Gunsteren, S. Billeter, A. Eising, P. Hünenberger, P. Krüger, A.
Mark, W. Scott and I. Tironi, Vdf Hochschulverlag AG an der ETH Zürich, Zürich 
1996, 86.
[47] H. Berendsen, J. Postma and W. Van Gunsteren in J. Hermans in
Intermolecular Forces, Vol. Reidel, Dordrecht, 1981.
[48] B. Hess, C. Kutzner, D. Van Der Spoel and E. Lindahl, Journal of chemical
theory and computation 2008, 4, 435-447.
[49] M. Parrinello and A. Rahman, Journal of Applied physics 1981, 52, 7182-
7190.
[50] a) T. Darden, D. York and L. Pedersen, The Journal of chemical physics
1993, 98, 10089-10092; b) U. Essmann, L. Perera, M. L. Berkowitz, T. Darden,
H. Lee and L. G. Pedersen, The Journal of chemical physics 1995, 103, 8577-
8593.
[51] W. Humphrey, A. Dalke and K. Schulten in VMD-Visual Molecular






             
      
              
   
 
Entry for the Table of Contents 
Why paroxetine is a potent cytochrome P450 inhibitor? DFT studies on the mechanism-based inactivation of P450 revealed the 
availability of two active sites on the structure of paroxetine vulnerable to hydroxylation by P450. the mechanisms of dehydration and
coordination to heme of hydroxylated paroxetine, docking analysis and MD simulations confirmed the compatibility and potency of
paroxetine as P450’ inhibitor.
11 
